Just in case anyone wants to know what the short-acting insulin market will look like in a few years after the arrival of a biosimilar look at the results released by Sanofi (NYSE: SNY) this morning. Per their press release;
“In the third quarter, global Diabetes sales decreased 10.0% to €1,552 million, reflecting lower Lantus® sales in the U.S. Third-quarter U.S. Diabetes sales were down 22.4% to €745 million. Year-to-date U.S. Diabetes sales decreased 20.2% to €2,398 million”
“Given increased visibility on sales performance, Sanofi refines its global . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.